ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pelacarsen

Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.

Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.

Drug pagePelacarsen: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 16, 201916 company-led studies, 4 open or runningNext primary completion: Feb 3, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only104 open or runningphase 3since Jul 16, 2019Jul 16, 2019Feb 3, 2028phase 3 · NCT06813911
Ionis Pharmaceuticals60 open or runningphase 2since Jan 31, 2017Apr 1, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ionis Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2015First study: phase 1 study in Elevated Lipoprotein(a)First studyNCT02414594 · 60 enrolled · Canada
  2. Jan 31, 2017Phase 2 study in Cardiovascular DiseasesNCT03070782 · 286 enrolled · United States, Canada, Denmark and more
  3. Jan 2, 20182 phase 1 studies in Cardiovascular DiseasesNCT03392051, NCT03426033
  4. Apr 3, 2018Phase 1 study in Renal InsufficiencyNCT03506854 · 16 enrolled · United States, Canada
  5. Dec 9, 2019Named pelacarsenINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ISIS 681257, TQJ230
  6. Apr 13, 2022Phase 1 study in Healthy ParticipantsNCT05337878 · 29 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Ionis Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05337878Healthy Participants · United States1CompletedDec 18, 201929
NCT03506854Renal Insufficiency · United States, Canada1CompletedOct 11, 201816
NCT03426033Cardiovascular Diseases · Canada1CompletedFeb 25, 201818
NCT03392051Cardiovascular Diseases · Canada1CompletedMar 18, 201818
NCT03070782Cardiovascular Diseases · United States, Canada, Denmark and more2CompletedJul 26, 2018286
NCT02414594Elevated Lipoprotein(a) · Canada1CompletedFeb 201660

How it is read

Names in the registry

  • “Pelacarsen”, 5 entries
  • “ISIS 681257”, 4 entries
  • “Pelacarsen (TQJ230)”, 2 entries
  • “TQJ230”, 2 entries
  • “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.